Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

50.42 -0.20 (-0.40%)
Streaming Delayed Price Updated: 2:42 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
Could AstraZeneca and Sanofi Win Big in RSV?
The companies have a promising RSV candidate. 
Via The Motley Fool
Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed... 
Via Benzinga
Daily Stock Analysis: Sanofi (SNY)
Sanofi's price per share closed at $51.50 yesterday. One year ago its price was $49.87. 
Via Talk Markets
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy
Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers BioVie (NASDAQ:BIVI) shares increased by 12.96% to $19.78 during Monday's pre-market session. The company's market cap stands at $275.2 million. Ocugen (... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) rose 58.3% to $78.90 in pre-market trading. Nicholas Jason Singer disclosed a 9.13% passive stake in Brooklyn... 
Via Benzinga
70 Firms Going Ex-Dividend Next Week, Including Walmart, BP And Pfizer
There are several well known large cap stocks going ex-dividend next week. Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to... 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually
Moderna Inc (NASDAQ: MRNA) plans to produce up to 3 billion doses in 2022, doubling capacity at contract sites in Switzerland and Spain run by Lonza Group... 
Via Benzinga
Exposures COVID-19
Moderna Stock Near Breakout As Company Boosts Its Covid Vaccines Outlook
Moderna boosted its forecast for Covid vaccine doses in 2021 and 2022, in a move early Thursday that could send Moderna stock into a breakout. 
Via Investor's Business Daily
Exposures COVID-19
Sanofi SA (SNY) Q1 2021 Earnings Call Transcript
SNY earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its... 
Via Benzinga
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Big Earnings Week Ahead To Close April In Style
Last week, the Dow Jones Industrial Average, S&P 500 and Nasdaq broke multiweek winning streaks with modest losses despite Friday's rally. This week's earnings will... 
Via Benzinga
Topics Stocks
Exposures US Equities
Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA)... 
Via Benzinga
Exposures COVID-19
Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants
Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc’s (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a... 
Via Benzinga
BioN­Tech CFO Sees Scope For Additional Pro­duc­tion Sites To Meet De­mand For COVID-19 Shots: Reuters
Pfizer Inc's (NYSE: PFE) COVID-19 vaccine partner BioNTech SE (NASDAQ: BNTX) is not ruling out further capacity expansion and new production... 
Via Benzinga
Exposures COVID-19
Here’s What $1,000 Invested In Vaccine Stocks Would Be Worth Now
It’s often said that with every crisis comes great opportunity. While such catastrophes do create upheaval and uncertainty in financial markets, they can also lead to new opportunities for investors,... 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.